Draft BASHH gonorrhoea guidelines recommend ciprofloxacin susceptibility testing
Updated Draft BASHH guidelines on the management of gonorrhoea indicate ciprofloxacin as preferential treatment over ceftriaxone if susceptibility is known.
ResistancePlus® GC will be the first commercially available molecular test to inform ciprofloxacin susceptibility status. Current gonorrhoea surveillance data indicate up to 80% of infections in some regions are susceptible to ciprofloxacin treatment.
Read full guidelines currently open for consultation.